查詢結果分析
來源資料
相關文獻
- [9358]F-FDG PET/CT in Patients with Cancer of Unknown Primary Site
- 分子生物技術在癌症轉移診斷的應用和展望
- T2脂肪飽和快速自旋回波及短時間反轉回復波序之MR成像在癌症脊椎轉移病人之比較
- Abdominal Wall Malignant Melanoma Metastasis to the Penis: A Case Report
- Tumor Invasion and Metastasis
- 以動物細胞篩選抗癌症轉移之生物活性物質
- 癌症如何轉移
- 五味子的機能性研究
- Left Neck Lump with Distant Metastasis from an Occult Primary Malignant Tumor: A Case Report
- 癌細胞想通過血管轉移洞悉「黏」力關鍵
頁籤選單縮合
題名 | [9358]F-FDG PET/CT in Patients with Cancer of Unknown Primary Site=以氟-18-氟化去氧葡萄糖正子-電腦斷層偵測原發部位未明癌症 |
---|---|
作者 | 張晉銓; 侯柏年; 林家揚; 李全孝; 陳毓雯; Chang, Chin-chuan; Hou, Po-nien; Lin, Chia-yang; Lee, Chuan-shaio; Chen, Yu-wen; |
期刊 | 核子醫學雜誌 |
出版日期 | 20090300 |
卷期 | 22:1 2009.03[民98.03] |
頁次 | 頁11-18 |
分類號 | 414.93 |
語文 | eng |
關鍵詞 | 氟-18-氟化去氧葡萄糖正子-電腦斷層掃描; 原發位置不明之癌症; 原發不明癌症症候群; 癌症轉移; FDG; PET/CT; Cancer of unknown primary site; CUP syndrome; Metastases; |
中文摘要 | 目的:這個回溯性研究目的是要探討以氟-18-氟化去氧葡萄糖正子-電腦斷層攝影,針對偵測原發部位不明之轉移癌的確切原發部位,所扮演的角色。 方法:在2006和月至2007年10月之間,共有24位(10位男性、14位女性;平均年龄55.5歲)經病理確定有轉移癌而原發位置不明之病人,轉介至我們正子電腦斷層攝影中心。所有的病人經傳统方法皆無法斷定原發腫瘤所在。每位病人依標准流程接受正子-電腦斷層攝影(空腹六小時、静脉注射370 MBq的氟-18-氟化去氧葡萄糖之後,接受全身正子-電腦斷層造影)。 結果:除了一位女性病患(#16)因爲已有乳癌病史而遭排除,其餘23位病人被纳入後續的分析。共有9位病患(39.1%)其正子-電腦斷層掃描可看出原發腫瘤位置、並在後續的手術得到證實。另外6位病患(26.1%)正子-電腦斷層掃描出現疑似原發腫瘤病灶,但並没有在後續的臨床结果得到證實。最後8位病患(38.1%)的正子電腦斷層掃描並没有發現明確原發腫瘤病灶。 結論:在這個研究中,原發位置不明之轉移癌症,約40%的病人可以籍由氟-18-氟化去氧葡萄糖正子-電腦斷層掃描偵測出原發病灶。如果可以藉由更大规模的病患数得到確認,那這另人鼓勵性的结果,將可支持往後遇到原發位置不明之癌症病人時,利用正子-電腦斷層掃描来做原發病灶的確認。 |
英文摘要 | Objective: This retrospective study was undertaken to address the results of PET/CT with 18F-FDG to determine the primary tumor origin of carcinomas with unknown primary site. Methods: Between February 2006 and October 2007, twenty-four patients (10 men, 14 women; mean age 55.5 years) with pathologically proven metastatic cancer of unknown primary site were referred to our PET/CT center. For all patients, extensive imaging was unsuccessful in localizing the primary site. Each patient underwent a PET/CT scan carried out according to a standard procedure (6 h of fasting, intravenous injection of 370 MBq of 18F-FDG and whole body image acquisition with a dedicated PET/CT scanner). Results: Twenty-three patients were eligible for analysis except a woman (#16) who had underlying breast cancer. In 9 patients (39.1%), FDG PET/CT showed a primary tumor site which was confirmed by follow-up or surgery. In another 6 patients (26.1%), the primary tumor site was suggested by FDG PET/CT but not confirmed by clinical outcome. No primary tumor was found on PET/CT image in the other 8 patients (38.1%). Conclusion: In our study, FDG PET/CT allowed the identification of primary tumor site in about forty percent of patients with unknown primary tumor. The encouraging results, if validated by larger patient population, support the use of PET/CT in patients with carcinoma of unknown primary origin. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。